Ivabradine in clinical practice: Benefits of If inhibition

European Heart Journal, Supplement

Volumn 7, Issue H, 2005, Pages

  Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Angina; Heart rate; Pharmacology

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; IVABRADINE; NITRIC ACID DERIVATIVE;

ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BRONCHOSPASM; CLINICAL TRIAL; COLD LIMB; DEPRESSION; DIZZINESS; FATIGUE; GASTROINTESTINAL DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART RATE; HUMAN; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SINUS NODE; VISUAL DISORDER;

EID: 24744469844     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui047     Document Type: Review

References (26)

1. Gibbons RJ, Abrams J, Chatterjee K; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. Circulation 2003;107:149-158.
2. Guth BD, Heusch G, Seitelberger R et al. Mechanisms of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 1987;60:738-746.
3. North of England Stable Angina Guideline Development Group. Summary version of evidence based guideline for the primary care management of angina. BMJ 1996;312:827-832.
4. Ko DT, Hebert PR, Coffey CS et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-357.
5. Tafreshi MJ, Weinacher AB. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy 1999;19:974-978.
6. Bortone AS, Hess OM, Gaglione A et al. Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation 1990;81:1225-1235.
7. Berdeaux A, Drieu la Rochelle C, Richard V et al. Opposed responses of large and small coronary arteries to propranolol during exercise in dogs. Am J Physiol 1991;261:H265-H270.
8. Simon L, Ghaleh B, Puybasset L et al. Coronary and hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659-666.
9. Krone W, Nagele H. Effects of antihypertensives on plasma lipids and lipoprotein metabolism. Am Heart J 1988;116:1729-1734.
10. Reneland R, Alvarez E, Anderson PE et al. Induction of insulin resistance by beta-blockade but not ACE inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000;14:175-180.
11. Diaz A, Bourassa MG, Guertin MC et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974.
12. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature 1986;324:470-473.
13. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991;34:23-40.
14. Bois P, Bescond J, Renaudon B et al. Mode of action of bradycardic agent, S16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118:1051-1057.
15. Thollon C, Cambarrat C, Vian J et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994;112:37-42.
16. Gardiner SM, Kemp PA, March JE et al. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 1995;115:579-586.
17. f inhibition: a novel mechanism of action. Eur Heart J 2003;5(Suppl. G):G19-G25.
18. Ragueneau I, Laveille C, Jochemsen R et al. Pharmacokinetic- pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998;64:192-203.
19. f inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 2003;107:817-823.
20. Bel A, Perrault LP, Faris B et al. Inhibition of the pacemaker current: a bradycardic therapy for off-pump coronary operations. Ann Thorac Surg 1998;66:148-152.
21. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S16257) in adult patients with normal baseline electrophysiology. Drugs RD 2003;4:83-89.
22. Manz M, Reuter M, Lauck G et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003;100:149-155.
23. Colin O, Ghaleh B, Hittinger L et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 2002;282:H672-H679.
24. f current inhibitor ivabradine versus atenolol in stable angina. Eur Heart J 2003;24(Suppl.):20.
25. f current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Eur Heart J 2004;25(Suppl.):878.
26. f current inhibitor ivabradine in patients with chronic stable angina. A one-year randomized, double blind, multicenter trial. Eur Heart J 2004;25(Suppl.):876.